Bioxyne Ltd (BXN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bioxyne Ltd (BXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12411
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bioxyne Ltd (Bioxyne), is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC (lactobacillus fermentum). It also develops a range of existing functional food and beauty products containing ingredients sourced from New Zealand. The company caters to consumer dietary supplements and functional foods markets. Its products are used as dietary supplement and foodstuffs and beverages. The company has manufacturing and distribution agreements with Chr. Hansen and Nu-Skin Enterprises. The company distributes its products across North America and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.

Bioxyne Ltd (BXN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Bioxyne Enters into Agreement with Datapharm Australia 10
Equity Offering 11
Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11
Bioxyne to Raise Funds through Private Placement of Shares 12
Bioxyne Completes Private Placement Of Shares For US$0.5 Million 13
Debt Offering 14
Bioxyne Announces Private Placement Of Notes For US$0.5 Million 14
Acquisition 15
Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For US$1.4 Million 15
Bioxyne Ltd – Key Competitors 16
Bioxyne Ltd – Key Employees 17
Bioxyne Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Feb 27, 2017: Bioxyne: Interim Financial Report For the Half Year ended 31 December 2016 19
Corporate Communications 21
May 01, 2018: Bioxyne: Non-Executive Director Appointment – Peter Charles Hughes-Hallett 21
Feb 15, 2018: Bioxyne: Resignation of Director 22
Product News 23
Dec 11, 2017: Positive Bioxyne Gut Health Clinical Trial Results 23
Other Significant Developments 24
Oct 29, 2018: Bioxyne: Quarterly report for the period ended 30 September 2018 24
Jul 27, 2018: Bioxyne: Quarterly report for the period ended 30 June 2018 25
Apr 27, 2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018 26
Jul 31, 2017: Bioxyne: Quarterly Report for the Period Ended 30 June 2017 27
Apr 27, 2017: Bioxyne: Quarterly Report for the Period Ended 31 March 2017 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Bioxyne Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bioxyne Enters into Agreement with Datapharm Australia 10
Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11
Bioxyne to Raise Funds through Private Placement of Shares 12
Bioxyne Completes Private Placement Of Shares For US$0.5 Million 13
Bioxyne Announces Private Placement Of Notes For US$0.5 Million 14
Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For US$1.4 Million 15
Bioxyne Ltd, Key Competitors 16
Bioxyne Ltd, Key Employees 17
Bioxyne Ltd, Subsidiaries 18

List of Figures
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Bioxyne Ltd (BXN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Skandinaviska Enskilda Banken AB:企業の戦略・SWOT・財務分析
    Skandinaviska Enskilda Banken AB - Strategy, SWOT and Corporate Finance Report Summary Skandinaviska Enskilda Banken AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Checkpoint Surgical LLC-医療機器分野:企業M&A・提携分析
    Summary Checkpoint Surgical LLC (Checkpoint Surgical) is a medical device company that offers neuro-protective surgery equipment. The company offers neuro-protective devices including checkpoint stimulators and locators; and checkpoint head and neck systems. Its checkpoint stimulators and locators p …
  • Sysmex Corp (6869):医療機器:M&Aディール及び事業提携情報
    Summary Sysmex Corp (Sysmex) is a supplier of medical devices. It researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. The company offers diagnostic instruments, reagents and laboratory inform …
  • Tsumura & co (4540):企業の財務・戦略的SWOT分析
    Tsumura & co (4540) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • OpenWay Group:企業の戦略的SWOT分析
    OpenWay Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Alcami Corp:企業の戦略的SWOT分析
    Alcami Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • SAS Group:企業のM&A・事業提携・投資動向
    SAS Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SAS Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Cleveland-Cliffs Inc:企業の戦略・SWOT・財務分析
    Cleveland-Cliffs Inc - Strategy, SWOT and Corporate Finance Report Summary Cleveland-Cliffs Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pfenex Inc (PFNX)-製薬・医療分野:企業M&A・提携分析
    Summary Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The company’s lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple scl …
  • Jubilant Biosys Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Jubilant Biosys Ltd (Jubilant Biosys), a subsidiary of Jubilant Life Sciences Ltd, is a provider of drug discovery and development solutions. The company offers functional discovery services such as toxicology models, computational chemistry, medicinal chemistry, structural biology, drug met …
  • InSightec Ltd:製品パイプライン分析
    Summary Insightec Ltd (InSightec), a subsidiary of Elbit Imaging Ltd is a medical device company that develops and markets MR ultrasound based medical devices. The company offers products through divisions such as neurosurgery, oncology and womens’ health. It offers services including commercial dev …
  • Suzlon Energy Ltd (SUZLON):企業の財務・戦略的SWOT分析
    Suzlon Energy Ltd (SUZLON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Guerbet SA (GBT):医療機器:M&Aディール及び事業提携情報
    Summary Guerbet SA (Guerbet) operates in the contrast-agent field. The company provides a wide range of pharmaceutical products, medical equipments and services for interventional imaging and diagnostic, to improve the diagnosis and treatment of patients. Its major products include diagnostic imagin …
  • Cimentos de Portugal SGPS SA:企業の戦略的SWOT分析
    Cimentos de Portugal SGPS SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Ansaldo Thomassen BV:企業の戦略的SWOT分析
    Ansaldo Thomassen BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • French National Institute of Health and Medical Research:医療機器:M&Aディール及び事業提携情報
    Summary French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immu …
  • Westar Energy Inc (WR):企業の財務・戦略的SWOT分析
    Westar Energy Inc (WR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Getinge AB (GETI B):企業の財務・戦略的SWOT分析
    Getinge AB (GETI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Esprinet SpA (PRT):企業の財務・戦略的SWOT分析
    Esprinet SpA (PRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Danaher Corp (DHR):企業の財務・戦略的SWOT分析
    Danaher Corp (DHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆